Germany’s medical cannabis industry erupted last week as telemedicine and pharmacy leaders dismantled government proposals to tighten prescription rules.
Operators who have crossed the line
Panelists from Grünhorn Group, Bloomwell Group and the VCA warned that a few unregulated platforms have abused the system.
Bosse cited a 1.7 million‑record leak, platforms using celebrity images and overseas prescribing networks with untraceable licences.
Grünhorn analysis showed 17.1 million people—over 80 % of the population—live more than 20 km from a specialised pharmacy, so most patients use mail‑order.
The pharmacy view
Christiane Neubauer of the VCA said specialist pharmacies face pressure from aggressive telemedicine operators.
Pharmacy chambers now require pharmacists to verify how each prescription is generated, questioning questionnaire or video consultation adequacy.
Neubauer said pharmacists must verify prescription generation, but patients need not answer; such checks involve sensitive data.
Pharmacies partnering with aggressive platforms face complicity accusations in medical advertising violations, especially with zero‑euro offers and heavy marketing, and price erosion after fees leaves thin margins that contributed to Lux 99’s insolvency.
‘We hear about the abuse, we see no measurable consequences’
Wichmann of Bloomwell said hospitalisation and traffic‑accident rates remain flat, and police report positive experiences with cannabis patients.
Wichmann said in‑person prescriptions are not automatically safer, noting research showing some patients receive up to 800 g per month from a single physician.
“Telemedicine is not less safe; it is more visible,” Wichmann said, citing the Federal Court of Justice’s March 2026 ruling that limits platforms from discussing indications.
Industry excluded from discussions
Panelists complained that the governing coalition has sidelined industry representatives, with Bloomwell’s meeting with CDU General Secretary Carsten Linnemann cancelled on the day of the symposium.
Under CDU Health Minister Nina Warken, dialogue sessions that were routine under the previous SPD ministry have stalled.
Bloomwell’s pilot to reimburse telemedicine prescriptions was rejected by all insurers despite offering a regional pain‑therapy cohort.
Industry proposals call for a certification regime covering age and identity verification, minimum consultation standards, and a legal retail route for adult‑use cannabis through pharmacies with THC and quantity caps (Pillar 2).
Bosse called Pillar 2 utopian in today’s Berlin climate but left the door open for long‑term consideration.
Survey data showed over 40 % of German cannabis patients would turn to the black market if the mail‑order ban proceeds.
